Mast Cell Research's Live MCAS Community Q&A with Dr. Lawrence Afrin #2 (May 2020)

In this Q&A session, Dr. Lawrence Afrin addresses a variety of questions from the Mast Cell Activation Syndrome (MCAS) community. He covers a range of topics including the genetic and biochemical pathways involved in histamine metabolism, the effects of stress on MCAS, and the interaction of other conditions like gastroparesis and seizures with MCAS. Dr. Afrin acknowledges the complexity of the syndrome, noting the variability in patient responses to different treatments. He emphasizes the importance of patience, persistence, and methodical testing of treatments in managing MCAS, which may include antihistamines, cromolyn, leukotriene blockers, and even specific oral rinses for oral symptoms. Timing discussion also touches on some practical challenges like the recent recall of ranitidine and the adaptation to alternative medications. Additionally, Dr. Afrin discusses the potential links between MCAS and COVID-19 complications, suggesting that the inflammatory response in MCAS could affect disease severity. Throughout the session, Dr. Afrin stresses that there is still much to learn about MCAS and encourages patients to work with healthcare providers willing to explore treatment options methodically.